Nanjing Shenghe Pharmaceutical

Nanjing Shenghe Pharmaceutical is a prominent Chinese pharmaceutical company dedicated to the research, development, and commercialization of innovative and high-quality medicines. Founded in 1996 and headquartered in Nanjing, the company has built a robust portfolio focusing on oncology, anti-infectives, and digestive system disorders. A key milestone for the company was the approval of Rezivertinib, a third-generation EGFR inhibitor for the treatment of non-small cell lung cancer. Shenghe operates a fully integrated value chain, including a dedicated research institute and multiple GMP-certified manufacturing facilities. The company continues to expand its pipeline through internal R&D and strategic international licensing agreements, such as its partnership for the antibiotic Lefamulin.